CHEMICALS SUMMARY PAGE

Dapsone

Summary Information
Classification Chemicals / Complex Chemical Agents / Type:

(This chemicals section is currently predominantly used in Wildpro to link different data types and demonstrate inter-relationships. It does not contain detailed information on the chemical itself.)

Alternative Names 4,4'diaminodiphenylsulphone
Notes Information in this page has been entered to support the current volumes of Wildpro and further information will be added as new volumes are completed. This page is not intended to substitute for the manufacturer's data sheet and the information is not yet complete for all species, or for all contra-indications etc.

CAUTION: Before any pharmaceutical product is used, the manufacturer's data sheet, containing information on uses, dosage and administration, contra-indications, warnings etc., should always be consulted. It is important to remember that licensing of pharmaceutical products for use in a particular species/condition, as well as mandatory meat and milk withdrawal times for food-producing animals, varies between countries and changes with time. Withdrawal times also may vary between different pharmaceutical formulations and depending on route of administration. In the EU, the prescription cascade must be followed (see LCofC1.2H and W564.Apr05.w1); note that specific restrictions apply for food-producing animals. In the USA, FARAD may be consulted regarding residues and meat and milk withdrawal times.

  • Antimycobacterial antibiotic which may be useful in the treatment of mycobacterial infections. (B658)
  • May be useful in the treatment of Pneumocyctis infections. (B658)
  • The exact mechanism of action is unknown. (B658, B682)
  • Used in the treatment of leprosy. (B682)
  • Slow absorption following oral administration, widely distributed in the body, excreted in bile and reabsorbed from the intestine, therefore persists in the body for 1-2 weeks after the cessation of administration. (B682)
  • In dogs: rapid, complete absorption, elimination half-life 6-10 hours, about 60% of the monacetyl metabolyte is plasma protein bound. (B658)
  • In humans, half life 10-50 hours and most of the monacetyl metabolyte is plasma protein bound. (B658)
  • Mainly eliminated via the kidneys, as conjugates and metabolites. (B658)
  • Hypersensitivity reactions to this drug can lead to anaemia. (B682)
  • Adverse effects can include hepatotoxicity, anaemia, thrombocytopaenia, neutropaenia, GIT effects, neuropathies, cutaneous drug eruptions and photosensitivity reactions.  Also a potent carcinogen. (B658)
    • Relatively contraindicated in cats, due to increased incidence of neurotoxicity, blood dyscrasias (e.g. aemolytic anaemia) and hepatotoxicity. (B658)
Administration
  • Dogs:
    • In the treatment of Mycobacterial infections: 1.1 mg/kg orally every six hours until remission, then 0.3 mg/kg every 8-12 hours. (B658)
    • In the treatment of Loxosceles sp. - Brown recluse spider bites: 1 mg/kg orally three times daily for  10 days. (B658)
  • Cats:
    • In the treatment of Mycobacterial infections: 8 mg/kg orally once daily for sis weeks. (B658)
    • In the treatment of feline leprosy: 1 mg/kg orally once daily. (B658)
  • Humans:
    • Initially 25 mg orally twice weekly, increasing slowly to reach 300 mg orally twice weekly. Administration for a period of several years is required in the treatment of leprosy. (B682)

Great Apes

Return to Top of Page